Armata Pharmaceuticals, Inc. (ARMP)
| Market Cap | 116.55M |
| Revenue (ttm) | 319,000 |
| Net Income (ttm) | -20.14M |
| Shares Out | 18.39M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $5.06 |
| Previous Close | $5.58 |
| Change ($) | -0.52 |
| Change (%) | -9.32% |
| Day's Open | 5.45 |
| Day's Range | 5.06 - 5.61 |
| Day's Volume | 42,716 |
| 52-Week Range | 2.52 - 10.48 |
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacte...
MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacte...
MARINA DEL REY, Calif., Nov. 12, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisel...
MARINA DEL REY, Calif., Oct. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacter...
MARINA DEL REY, Calif., Oct. 26, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bact...
Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.
MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bact...
MARINA DEL REY, Calif., Sept. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bac...
MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc.
MARINA DEL REY, Calif., Aug. 13, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc.
About ARMP
Armata Pharmaceuticals, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating disease... [Read more...]
| Industry Biotechnology | |
| CEO Todd Patrick | Employees 33 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol ARMP |
Analyst Forecasts
According to 4 analysts, the average rating for ARMP stock is "Buy." The 12-month stock price forecast is 7.25, which is an increase of 43.28% from the latest price.